

## Special Issue

# Radiotherapy in Gynecological Cancer: State of the Art

### Message from the Guest Editors

This Special Issue of *Cancers* considers the quick evolution of radiation oncology in the gynaecological tumour sites of endometrial, cervical, vaginal and vulvar cancers. Considering the variety of advances achieved in the last decade, radiotherapy in gynaecological cancer has become increasingly well established and there has been an increase in cancer treatment results. At present, new indications and new techniques to be employed in this scenario include intensity-modulated radiotherapy, image-guided external beam irradiation, image-guided brachytherapy, stereotactic body radiation and intraoperative radiotherapy between others. Recently, tumour markers have been related to radiotherapy indications, leading omics-based and other adjuvant treatments to now be in the pipeline. Artificial intelligence is currently being developed for future use in this field. This is a promising Special Issue that aims to establish the state of the art in the radiotherapy of gynaecological cancers via reviews or research articles developed by radiation oncologists, medical oncologists and medical physicists, with a view into the future.

---

### Guest Editors

Dr. Angeles Rovirosa

Dr. Gabriella Macchia

Dr. Luca Tagliaferri

---

### Deadline for manuscript submissions

closed (20 April 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/184046](https://mdpi.com/si/184046)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)